[1] FU Y,SUN Y,ZHOU M,et al.Therapeutic potential of progranulin in hyperhomocysteinemia-induced cardiorenal dysfunction[J].Hypertension (Dallas,Tex:1979),2017,69(2):259-266.
[2] FU Y,SUN Y,WANG M,et al.Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism[J].Cell Metabolism,2020,32(6):1052-1062.e8.
[3] CATHERINE M S.The ins-and-outs of podocyte lipid metabolism[J].Kidney Int,2020,98(5):1087-1090.
[4] MOORHEAD J F,CHAN M K,EL-NAHAS M,et al.Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease[J].Lancet,1982,2(8311):1309-1311.
[5] BOBULESCU I A.Renal lipid metabolism and lipotoxicity[J].Curr Opin Nephrol Hypertens,2010,19(4):393-402.
[6] D'AGATI V D,CHAGNAC A,DE VRIES A P,et al.Obesity-related glomerulopathy:clinical and pathologic characteristics and pathogenesis[J].Nat Rev Nephrol,2016,12(8):453-471.
[7] FORNONI A,MERSCHER S,KOPP J B.Lipid biology of the podocyte——new perspectives offer new opportunities[J].Nat Rev Nephrol,2014,10(7):379-388.
[8] PISETSKY D S.HMGB1:a smoking gun in lupus nephritis?[J].Arthritis Res Ther,2012,14(2):112.
[9] HERMAN-EDELSTEIN M,THOMAS M C,THALLAS-BONKE V,et al.Dedifferentiation of immortalized human podocytes in response to transforming growth factor-beta:a model for diabetic podocytopathy[J].Diabetes,2011,60(6):1779-1788.
[10] SUN L,HALAIHEL N,ZHANG W,et al.Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus[J].J Biol Chem,2002,277(21):18919-18927.
[11] XUE L,QI H,ZHANG H,et al.Targeting SREBP-2-regulated mevalonate metabolism for cancer therapy[J].Front Oncol,2020,10:1510.
[12] BOITIER E,GAUTIER J C,ROBERTS R.Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models:relevance for human health and disease[J].Comp Hepatol,2003,2(1):3.
[13] BECK F,PLUMMER S,SENIOR P V,et al.The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat[J].Proc Biol Sci,1992,247(1319):83-87.
[14] TONTONOZ P,HU E,GRAVES R A,et al.mPPAR gamma 2:tissue-specific regulator of an adipocyte enhancer[J].Genes Dev,1994,8(10):1224-1234.
[15] XING G,ZHANG L,ZHANG L,et al.Rat PPAR delta contains a CGG triplet repeat and is prominently expressed in the thalamic nuclei[J].Biochem Biophys Res Commun,1995,217(3):1015-1025.
[16] WILDING J P.PPAR agonists for the treatment of cardiovascular disease in patients with diabetes[J].Diabetes Obes Metab,2012,14(11):973-982.
[17] ZHOU Y,KONG X,ZHAO P,et al.Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury[J].Kidney Int,2011,79(12):1302-1311.
[18] TONTONOZ P,SPIEGELMAN B M.Fat and beyond:the diverse biology of PPARgamma[J].Annu Rev Biochem,2008,77:289-312.
[19] CAMMISOTTO P G,BENDAYAN M.Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli[J].J Mol Histol,2008,39(6):579-584.
[20] KAMPE K,SIEBER J,ORELLANA J M,et al.Susceptibility of podocytes to palmitic acid is regulated by fatty acid oxidation and inversely depends on acetyl-CoA carboxylases 1 and 2[J].Am J Physiol Renal Physiol,2014,306(4):F401-409.
[21] DECLEVES A E,ZOLKIPLI Z,SATRIANO J,et al.Regulation of lipid accumulation by AMK-activated kinase in high fat diet-induced kidney injury[J].Kidney Int,2017,92(3):769.
[22] YANG Q,ZHOU Y,SUN Y,et al.Will sirtuins be promising therapeutic targets for TBI and associated neurodegenerative diseases?[J].Front Neurosci,2020,14:791.
[23] GIACCONI R,CHIODI L,BOCCOLI G,et al.Reduced levels of plasma selenium are associated with increased inflammation and cardiovascular disease in an Italian elderly population[J].Exp Gerontol,2021,145:111219.
[24] ZANG Y,FAN L,CHEN J,et al.Improvement of lipid and glucose metabolism by capsiate in palmitic acid-treated HepG2 cells via activation of the AMPK/SIRT1 signaling pathway[J].J Agric Food Chem,2018,66(26):6772-6781.
[25] OKADA-IWABU M,YAMAUCHI T,IWABU M,et al.A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity[J].Nature,2013,503(7477):493-499.
[26] OKADA-IWABU M,IWABU M,UEKI K,et al.Perspective of small-molecule adipoR agonist for type 2 diabetes and short life in Obesity[J].Diabetes Metab J,2015,39(5):363-372.
[27] DUCASA G M,MITROFANOVA A,MALLELA S K,et al.ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes[J].J Clin Invest,2019,129(8):3387-3400.
[28] PEDIGO C E,DUCASA G M,LECLERCQ F,et al.Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury[J].J Clin Invest,2016,126(9):3336-3350.
[29] YANG Y,YANG Q,YANG J,et al.Angiotensin II induces cholesterol accumulation and injury in podocytes[J].Sci Rep,2017,7(1):10672.
[30] HERMAN-EDELSTEIN M,SCHERZER P,TOBAR A,et al.Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy[J].J Lipid Res,2014,55(3):561-572.
[31] LYU J,IMACHI H,FUKUNAGA K,et al.AngiotensinⅡ induces cholesterol accumulation and impairs insulin secretion by regulating ABCA1 in beta cells[J].J Lipid Res,2018,59(10):1906-1915.
[32] FALKEVALL A,MEHLEM A,PALOMBO I,et al.Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease[J].Cell Metab,2017,25(3):713-726.
[33] ZELENCOVA-GOPEJENKO D,VIDEJA M,GRANDANE A,et al.Heart-type fatty acid binding protein binds long-chain acylcarnitines and protects against lipotoxicity[J].Int J Mol Sci,2023,24(6):5528.
[34] CHEN Y,HE L,YANG Y,et al.The inhibition of Nrf2 accelerates renal lipid deposition through suppressing the ACSL1 expression in obesity-related nephropathy[J].Renal Failure,2019,41(1):821-831.
[35] KRUGER C,BURKE S J,COLLIER J J,et al.Lipid peroxidation regulates podocyte migration and cytoskeletal structure through redox sensitive RhoA signaling[J].Redox Biology,2018,16:248-254.
[36] GE M,FONTANESI F,MERSCHER S,et al.The vicious cycle of renal lipotoxicity and mitochondrial dysfunction[J].Front Physiol,2020,11:732.
[37] ZHANG J,WU Y,ZHANG J,et al.ABCA1 deficiency-mediated glomerular cholesterol accumulation exacerbates glomerular endothelial injury and dysfunction in diabetic kidney disease[J].Metabolism,2023,139:155377.
[38] 孙珺,郭兆安.肾脏疾病中线粒体脂代谢与脂毒性的研究进展[J].生命的化学,2023,43(4):549-557.
[39] DUCASA G M,MITROFANOVA A,FORNONI A.Crosstalk between lipids and mitochondria in diabetic kidney disease[J].Curr Diabetes Rep,2019,19(12):144.
[40] DEHNAVI S,KIANI A,SADEGHI M,et al.Targeting AMPK by statins:a potential therapeutic approach[J].Drugs,2021,81(8):923-933.
[41] JIANG W,HU J W,HE X R,et al.Statins:a repurposed drug to fight cancer[J]. J Exp Clin Cancer Res,2021,40(1):241.
[42] HUANG T S,WU T,WU Y D,et al.Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice[J].Nat Commun,2023,14(1):390.
[43] GAI Z,WANG T,VISENTIN M,et al.Lipid accumulation and chronic kidney disease[J].Nutrients,2019,11(4):722.
[44] MITROFANOVA A,MERSCHER S,FORNONI A.Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease[J].Nat Rev Nephrol,2023,19(10):629-645.
[45] KIM Y,LIM J H,KIM M Y,et al.The adiponectin receptor agonist AdipoRon ameliorates diabetic nephropathy in a model of type 2 diabetes[J].J Am Soc Nephrol,2018,29(4):1108-1127.
[46] FISMAN E Z,TENENBAUM A.Adiponectin:a manifold therapeutic target for metabolic syndrome,diabetes,and coronary disease?[J].Cardiovasc Diabetol,2014,13:103.
[47] MA T,TIAN X,ZHANG B,et al.Low-dose metformin targets the lysosomal AMPK pathway through PEN2[J].Nature,2022,603(7899):159-165.
[48] KWON S,KIM Y C,PARK J Y,et al.The long-term effects of metformin on patients with type 2 diabetic kidney disease[J].Diabetes Care,2020,43(5):948-955.
[49] WAKINO S,HASEGAWA K,ITOH H.Sirtuin and metabolic kidney disease[J].Kidney Int,2015,88(4):691-698.
[50] MA F,WU J,JIANG Z,et al.P53/NRF2 mediates SIRT1's protective effect on diabetic nephropathy[J].Biochim Biophys Acta Mol Cell Res,2019,1866(8):1272-1281.
[51] XU Y,LIU Q,XU Y,et al.Rutaecarpine suppresses atherosclerosis in ApoE-/-mice through upregulating ABCA1 and SR-BI within RCT[J].J Lipid Res,2014,55(8):1634-1647.
[52] MA J,GUO D,JI X,et al.Composite hydrogel for spatiotemporal lipid intervention of tumor milieu[J].Adv Mater,2023,35(14):e2211579.
[53] SUN Y,CUI S,HOU Y,et al.The updates of podocyte lipid metabolism in proteinuric kidney disease[J].Kidney Dis (Basel),2021,7(6):438-451.
[54] GONZÁLEZ-ALBARRÁN O,MORALES C,PÉREZ-MARAVER M,et al.Review of SGLT2i for the treatment of renal complications:experience in patients with and without T2D[J].Diabetes Ther,2022,13(Suppl 1):35-49.
[55] PEI K,GUI T,LI C,et al.Recent progress on lipid intake and chronic kidney disease[J].Biomed Res Int,2020,2020:3680397.
[56] WIVIOTT S D,RAZ I,BONACA M P,et al.Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2019,380(4):347-357.
[57] JIANG T,WANG X X,SCHERZER P,et al.Farnesoid X receptor modulates renal lipid metabolism,fibrosis,and diabetic nephropathy[J].Diabetes,2007,56(10):2485-2493.
[58] WANG X X,JIANG T,SHEN Y,et al.Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model[J].Diabetes,2010,59(11):2916-2927.
[59] THOMAS C,GIOIELLO A,NORIEGA L,et al.TGR5-mediated bile acid sensing controls glucose homeostasis[J].Cell Metabolism,2009,10(3):167-177.
[60] WANG X X,WANG D,LUO Y,et al.FXR/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity[J].J Am Soc Nephrol,2018,29(1):118-137.
[61] ZIMMER S,GREBE A,BAKKE S S,et al.Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming[J].Sci Transl Med,2016,8(333):333ra50.
[62] ZHAO Y,HE L,WANG T,et al.2-hydroxypropyl-β-cyclodextrin regulates the epithelial to mesenchymal transition in breast cancer cells by modulating cholesterol homeostasis and endoplasmic reticulum stress[J].Metabolites,2021,11(8):562. |
